Effect of Lactobacillus paracasei CNCM I‐1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial

Abstract

This pilot study shows that CNCM I-1572 is able to modulate gut microbiota structure/function and reduce immune activation in IBS. As no statistically significant effect on IBS-symptoms was found, further studies are necessary to determine the role of this probiotic in IBS. The study was registered at ClinicalTrials.gov registry under identifier NCT02371499.

Fecal Clostridiales distribution and short‐chain fatty acids reflect bowel habits in irritable bowel syndrome

“…NCT02371499), whose primary endpoint was the assessment of the effect of Lactobacillus paracasei CNCM I‐1572 (LCDG) on the IBS clinical symptoms. The design and results of the PROBE‐IBS trial are described in Cremon and colleagues (). In brief, PROBE‐IBS consisted of a two‐week run‐in phase, after which the volunteers were randomly assigned to take either LCDG twice daily for four weeks or a placebo (treatment A).…”

“…IBS subtypes were classified according to the Rome III criteria and based on Bristol Stool Form scale characteristics (Longstreth et al ., ). Information and biological specimens were collected every four weeks at five consecutive time points (visits V1–V5) according to the trial design described by Cremon and colleagues (). One participant (belonging to the IBS‐D subgroup) dropped out after visit V3 and, consequently, 198 fecal samples were collected.…”

“…16S rRNA gene profiling analyses were performed on all samples, whereas SCFAs were quantified in the 5 fecal samples of 37 patients (i.e., a total of 185 samples; IBS‐C, n = 12; IBS‐D, n = 11; IBS‐M, n = 3; IBS‐U, n = 11) due to insufficient specimens. Data from Bristol stool scale, anxiety/depression scales, and IgA and cytokine data were available as described in Cremon and colleagues (). Correlation analyses were performed using data from a subgroup of 150 samples (30 patients) instead of 200 (40 patients) because we removed samples with immunological data below the detection limit.…”

Modulatory effect of Lactobacillus acidophilus KLDS 1.0738 on intestinal short‐chain fatty acids metabolism and GPR41/43 expression in β‐lactoglobulin–sensitized mice

“…Shi et al reported that the protective effects of Lactobacillus cocktails on alleviating intestinal inflammation were related to restoring the cefixime‐induced gut microbiota and production of SCFAs in a murine model . Cremon et al studied 40 patients with irritable bowel syndrome (IBS) and observed that the risk of IBS could be reduced by Lactobacillus paracasei through modulating the gut microbiota structure and increasing the fecal acetate and butyrate levels . In addition, Simonyte Sjödin et al reported that probiotics regulating the gut microbiota–SCFA axis played a role in inducing the anti‐inflammatory response…”

“…2 Cremon et al studied 40 patients with irritable bowel syndrome (IBS) and observed that the risk of IBS could be reduced by Lactobacillus paracasei through modulating the gut microbiota structure and increasing the fecal acetate and butyrate levels. 3 In addition, Simonyte Sjödin et al reported that probiotics regulating the gut microbiota-SCFA axis played a role in inducing the antiinflammatory response. 4 Canani et al indicated that treatment with Lactobacillus rhamnosus GG-supplemented formula promoted tolerance in infants with CMA by increasing the relative abundance of butyrate-producing bacterial strains and fecal butyrate levels.…”